- Reaction score
- 342
“
This study aims to evaluate the safety and efficacy of HMI-115 versus a placebo in pre-menopausal women with moderate to severe Endometriosis associated pain.
The study will have two parts: Part 1 and Part 2. Part 1 will determine the safety and efficacy of HMI 115 at 60 mg, 120 mg, and 240 mg. Only when the safety and efficacy have been evaluated by the Sponsor in Part 1 of the study will eligible subjects (new subjects) be admitted to Part 2 of the study. Part 2 of the study will determine the safety and efficacy of HMI 115 at 480 mg every 4 weeks (Q4W) and every 2 weeks (Q2W).
“
ClinicalTrials.gov
clinicaltrials.gov
No mention about Androgenetic Alopecia
From our perspective, at least it's more safety data (even if it's in women).